Amarin reported $162.41M in Current Liabilities for its fiscal quarter ending in March of 2025.


Current Liabilities Change Date
AbbVie USD 36.4B 2.35B Mar/2025
Alnylam Pharmaceuticals USD 1.3B 225.22M Jun/2025
Amarin USD 162.41M 17.54M Mar/2025
AstraZeneca USD 33.54B 4.41B Jun/2025
DBV Technologies USD 49.42M 9.04M Jun/2025
GlaxoSmithKline GBP 20.38B 453M Jun/2025
Halozyme Therapeutics USD 134.28M 16.1M Jun/2025
Ionis Pharmaceuticals USD 897.24M 646.94M Jun/2025
Neurocrine Biosciences USD 546.3M 23.4M Jun/2025
Novartis USD 31.71B 95M Jun/2025